Cargando…

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pascual, Tomas, Apellániz-Ruiz, María, Pernaut, Cristina, Cueto-Felgueroso, Cecilia, Villalba, Pablo, Álvarez, Carlos, Manso, Luis, Inglada-Pérez, Lucia, Robledo, Mercedes, Rodríguez-Antona, Cristina, Ciruelos, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519037/ https://www.ncbi.nlm.nih.gov/pubmed/28727815 http://dx.doi.org/10.1371/journal.pone.0180192

Ejemplares similares

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation
por: Espinosa, Marta, et al.
Publicado: (2018)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2020)

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2022)

Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients
por: Pena-Couso, Laura, et al.
Publicado: (2022)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Self-organization of network dynamics into local quantized states
por: Nicolaides, Christos, et al.
Publicado: (2016)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition
por: Yamamoto, Kazuhiro, et al.
Publicado: (2013)

Durvalumab/everolimus: Lung toxicity and pulmonary sarcoidosis: 2 case reports
Publicado: (2021)

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
por: Kuik, Kelvin Teck-Hong, et al.
Publicado: (2014)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Everolimus-associated Acute Kidney Injury in Patients with Metastatic Breast Cancer
por: Chandra, A., et al.
Publicado: (2017)

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab
por: Manso, L, et al.
Publicado: (2009)

Long-term infant feeding roles in triggering uncontrolled inflammatory responses
por: Verd, Sergio, et al.
Publicado: (2022)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study
por: Noreikaitė, Aurelija, et al.
Publicado: (2017)

Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
por: Labriffe, Marc, et al.
Publicado: (2022)

Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects
por: Zha, Jiuhong, et al.
Publicado: (2022)

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling
por: Menzel, Karsten, et al.
Publicado: (2023)

A Metric of Influential Spreading during Contagion Dynamics through the Air Transportation Network
por: Nicolaides, Christos, et al.
Publicado: (2012)

The role of pore fluids in supershear earthquake ruptures
por: Pampillón, Pedro, et al.
Publicado: (2023)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
por: Werner, Dominique, et al.
Publicado: (2013)

CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
por: Caruso, Damiano, et al.
Publicado: (2022)

Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics
por: Itohara, Kotaro, et al.
Publicado: (2022)

Teoría económica
por: Pernaut Ardanaz, Manuel
Publicado: (1970)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Overexpression of miR‐483‐5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma
por: Castro‐Vega, Luis Jaime, et al.
Publicado: (2020)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging
por: Dejust, Sebastien, et al.
Publicado: (2018)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9i7iqcjqcao861gdnctjmpecm2